What is HC Wainwright’s Forecast for NERV FY2026 Earnings?

Minerva Neurosciences, Inc (NASDAQ:NERV – Free Report) – Stock analysts at HC Wainwright lifted their FY2026 earnings estimates for Minerva Neurosciences in a report issued on Monday, November 9th. HC Wainwright analyst D. Tsao now anticipates that the biopharmaceutical company will earn ($0.70) per share for the year, up from their prior forecast of ($0.73). The consensus estimate for Minerva Neurosciences’ current full-year earnings is ($0.70) per share.

Minerva Neurosciences (NASDAQ:NERV – Get Free Report) last announced its quarterly earnings data on Friday, November 6th. The biopharmaceutical company reported ($1.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($1.46).

NERV has been the subject of several other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Minerva Neurosciences in a report on Monday, September 21st. Jefferies Financial Group upgraded Minerva Neurosciences from a “hold” rating to a “mixed” rating and increased their price target for the stock from $7.50 to $10.00 in a research note on Friday, August 14th. Wall Street Zen cut Minerva Neurosciences from a “hold” rating to a “sell” rating in a report on Saturday, October 31st. Finally, Zacks Research upgraded Minerva Neurosciences from a “strong sell” rating to a “hold” rating in a research report on Friday, October 9th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Minerva Neurosciences presently has a consensus rating of “Hold” and an average target price of $10.33.

Read Our Latest Report on Minerva Neurosciences

Minerva Neurosciences Stock Performance

Shares of NERV stock opened at $2.12 on Wednesday. Minerva Neurosciences has a one year low of $1.96 and a one year high of $8.80. The company’s fifty day moving average price is $2.84 and its 200-day moving average price is $4.75.

Institutional Trading of Minerva Neurosciences

Several hedge funds have recently bought and sold shares of the stock. Seven Fleet Capital Management LP purchased a new position in shares of Minerva Neurosciences during the first quarter valued at about $6,855,000. DV Trading LLC bought a new stake in shares of Minerva Neurosciences in the first quarter worth about $5,358,000. Janus Henderson Group PLC increased its holdings in shares of Minerva Neurosciences by 47,614.0% in the first quarter. Janus Henderson Group PLC now owns 4,294,259 shares of the biopharmaceutical company’s stock worth $25,873,000 after purchasing an additional 4,285,259 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Minerva Neurosciences by 19.8% in the third quarter. Goldman Sachs Group Inc. now owns 172,461 shares of the biopharmaceutical company’s stock worth $578,000 after buying an additional 28,507 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Minerva Neurosciences in the second quarter worth about $419,000. Hedge funds and other institutional investors own 34.56% of the company’s stock.

About Minerva Neurosciences

(Get Free Report)

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts. It focuses on developing treatments for central nervous system disorders and does not have marketed products. The company’s principal drug candidate has been roluperidone, an oral medicine studied for negative symptoms of schizophrenia. The candidate remains investigational; its development has included clinical trials and regulatory review in the United States. Minerva’s earlier research pipeline has also included MIN-301, a biologic candidate studied for Parkinson’s disease.

Recommended Stories

Earnings History and Estimates for Minerva Neurosciences (NASDAQ:NERV)

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.